Taiwanese President Tsai Ing-wen received her first dose of the island’s domestically developed CCP (Chinese Communist Party) virus, commonly known as the novel coronavirus, vaccine on Aug. 23, launching its rollout to the public. The vaccine, made by Medigen Vaccine Biologics Corp., was given emergency approval by regulators in July using a shortcut that prompted fierce opposition from parts of Taiwan’s medical and scientific community. Taiwanese regulators bypassed the large-scale, longer-term studies that are typically used to approve vaccines. Instead, they compared the level of antibodies that Medigen’s vaccine was able to generate with that of AstraZeneca’s vaccine, which has been approved by many governments and has undergone the full three stages of clinical trials. The two-dose Medigen protein subunit vaccine uses a piece of the coronavirus to teach the body to mount an immune response. The decision to give approval based on the new standard prompted an expert from …